
NEWS RELEASE

ix Biopharma enters strategic cooperation framework agreement with China Resources Pharmaceutical Commercial Group Co., Ltd

Singapore, 6 April 2021 – Specialty pharmaceutical company **ix Biopharma Ltd** (SGX:42C) (“ix Biopharma” or “the Company”, and together with its subsidiaries, “the Group”) is pleased to announce that it has entered into a strategic cooperation framework agreement (“**Strategic Cooperation Agreement**”) with China Resources Pharmaceutical Commercial Group Co., Ltd. (华润医药商业集团有限公司) (“**CRPCG**”).

Under the Strategic Cooperation Agreement, ix Biopharma and CRPCG will engage in all-round cooperation in respect of ix Biopharma’s pipeline of innovative sublingual pharmaceutical and nutraceutical products in China. The parties will determine the appropriate products and model of cooperation, which may be via licensing or joint venture, and CRPCG will undertake the full scope of operation in China including registration, manufacturing, distribution and promotion.

ix Biopharma has developed a patented drug delivery platform technology, WaferiX. WaferiX delivers drug sublingually via the mucosa for better absorption, faster onset of action and predictable effect. The WaferiX delivery platform is particularly useful for drug repurposing which is a growing trend with a global market worth US\$34 billion. Drug repurposing is where existing approved drugs are developed into new drugs targeting different indications or a different route of administration, at a lower development cost and risk.

CRPCG is part of the China Resources Pharmaceutical Group, which is the second largest pharmaceutical manufacturer and one of the three largest pharmaceutical distributors by revenue in China. Through this strategic cooperation, CRPCG will have access to ix Biopharma’s rich pipeline of unique sublingual products, formulated using WaferiX, to meet underserved medical needs across many health conditions. By leveraging on each other’s strengths and capabilities, both parties will cooperate to seize the immense opportunities in the China market.

CRPCG commented that, *“The WaferiX sublingual delivery technology is unique in the pharmaceutical industry. Using this versatile platform, ix Biopharma has developed many exciting products which have excellent commercial potential in the China market. CRPCG is willing to support the market entry and launch of these products with its extensive infrastructure and comprehensive capabilities covering product registration to commercialisation.”*

Ms Eva Tan, Chief Commercial Officer of the Company, said: *“The Chinese pharmaceutical and healthcare industry is undergoing tremendous growth. This has spurred intense competition amongst Chinese companies to invest in, and bring to market, differentiated products with superior clinical benefit. We are delighted that China Resources Pharmaceutical Group recognises the enormous potential that our drugs and nutraceuticals have in the China*

market, and we look forward to tapping on their deep experience and market-leading distribution network to access the China market.”

The Strategic Cooperation Agreement serves as a guidance for the future long-term cooperation between the parties and as a basis for binding contracts to be entered into by the parties.

About CR Pharmaceutical and China Resources Pharmaceutical Group Limited

China Resources Pharmaceutical Group Limited (华润医药集团有限公司) (stock code: 3320.HK) is a leading integrated pharmaceutical company in China, with business spanning manufacturing, distribution and retail of pharmaceutical and healthcare products. CRPCG is the primary profit centre of China Resources Pharmaceutical Group Limited. Since its listing in 2016 on the Hong Kong Stock Exchange, the Company has been included in a number of capital market indexes such as MSCI China Index, FTSE Global Large Cap Index, constituent stock of Hang Seng Composite Large Cap Index and Hang Seng Corporate Sustainability Index. It operates a national distribution network comprising 178 logistics centres and its sales network covers all 31 provinces (municipalities and autonomous regions) and Hong Kong and Macao Special Administrative Regions in China. It directly distributes products to hospitals and other medical institutions across the country and operates one of the largest retail pharmacy networks in China, comprising over 850 pharmacies under national or regional premium brands - “Teck Soon Hong (德信行)”

- End -

About iX Biopharma Ltd

iX Biopharma is a specialty pharmaceutical and nutraceutical company listed on the Catalist board of the Singapore Exchange Securities Trading Limited (SGX-ST), operating a fully integrated business model from drug development to manufacturing and supply, with facilities in Australia. The Group is focused on the development and commercialisation of therapies for diseases of the central nervous system using novel, patent-protected formulations for sublingual delivery.

iX Biopharma's pipeline of products under development includes Wafermine (ketamine wafer) and BnoX (buprenorphine wafer) for pain management. iX Biopharma's drugs for the treatment of erectile dysfunction, Wafesil, a sublingual sildenafil wafer, and Silcap, have been registered in Australia and Singapore. iX Biopharma has developed Xativa, the world's first freeze-dried sublingual medicinal cannabis wafer.

The Group's nutraceuticals division, Entity Health Limited, is engaged in the development and commercialisation of nutraceutical products that address specific conditions and improve quality of life. It distributes its Entity line of nutraceutical products in Australia through more than 250 pharmacies and health food shops, in China through its flagship stores on Tmall Global and JD Worldwide, and globally through its online store.

Contact for media:

Yee Chia Hsing

Director of Corporate Affairs

T: +65 6235 2270

E: chiahsing.yee@ixbiopharma.com

Eva Tan

Chief Commercial Officer

T: +65 62353212

E: eva.tan@ixbiopharma.com

This announcement has been reviewed by the Company's sponsor, CIMB Bank Berhad, Singapore Branch ("Sponsor") in accordance with Rule 226(2)(b) of the Catalist Rules. This announcement has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement. The contact person for the Sponsor is Mr. Eric Wong, Director, Investment Banking, Singapore. The contact particulars are 50 Raffles Place, #09-01 Singapore Land Tower, Singapore 048623, telephone: (65) 6337-5115.